# Autolus Therapeutics plc（納斯達克代碼：AUTL）宣布其提交至美國臨床腫瘤學會（ASCO）年會的摘要已在線發表。

*biotech · news · 2026-05-21 · The Manila Times*

## Key points

- Obe-cel 在患有 B-ALL 及體外病灶的患者中達成 59% 的整體反應率。
- Obe-cel 在體外病灶患者中的中位反應持續時間為 42.6 個月。
- Ib/II 期 FELIX 研究的事後分析涵蓋 127 名患者，其中 21% 有體外病灶。
- Obe-cel 在有無體外病灶的患者中均展現出良好的安全性結果。

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 - June 2, 2026, in Chicago, Illinois. "Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a potential treatment option for this difficult to treat population of patients,” said Matthias Will, MD, Autolus Chief Development Officer. Abstract 6517 Title: The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD). Session Type and Track: Rapid Oral Abstract: Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant. Session Date and Time: May 30, 2026; 1:15 - 2:45PM CDT Session Room: E450a Abstract Number: 6517 Presentation time: 2:27 - 2:33pm CDT Presenting Author: Jae Park, MD, Director, Adult ALL Program | Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA Summary: A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL received obe-cel using a tumor burden-guided dosing strategy to minimize toxicity. Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Of 127 obe-cel infused patients, 27 (21%) had EMD at LD. Among responders, duration of response in patients with EMD was 42.6 months, and the overall remission rate was 59%. Overall, these findings suggest a positive benefit-risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD. About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com. Contact: Amanda Cray +1 617-967-0207

**Companies:** Autolus Therapeutics plc
**Countries:** United Kingdom, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713)

---

Canonical: https://newsio.io/zh-TW/n/ea097256-0d70-45a2-b52d-3e1326f0691a/autolus-therapeutics-plcautlasco
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works